FY2028 Earnings Estimate for LENZ Issued By Leerink Partnrs

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Leerink Partnrs lifted their FY2028 EPS estimates for LENZ Therapeutics in a research report issued on Tuesday, October 15th. Leerink Partnrs analyst M. Goodman now anticipates that the company will earn $2.00 per share for the year, up from their previous forecast of ($2.00). The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($3.15) per share.

Other analysts have also recently issued research reports about the company. Piper Sandler reaffirmed an “overweight” rating and set a $36.00 price target on shares of LENZ Therapeutics in a research report on Thursday, August 15th. William Blair raised LENZ Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. HC Wainwright began coverage on shares of LENZ Therapeutics in a report on Monday, August 12th. They issued a “buy” rating and a $38.00 price target on the stock. Finally, Raymond James initiated coverage on shares of LENZ Therapeutics in a research note on Friday, September 27th. They set an “outperform” rating and a $37.00 price objective for the company. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, LENZ Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $35.40.

LENZ Therapeutics Price Performance

Shares of LENZ opened at $27.99 on Friday. The company’s fifty day moving average price is $23.21 and its 200-day moving average price is $20.30. LENZ Therapeutics has a 1-year low of $14.07 and a 1-year high of $29.82.

LENZ Therapeutics (NASDAQ:LENZ) last released its earnings results on Wednesday, August 14th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.09.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. American International Group Inc. purchased a new stake in LENZ Therapeutics in the 1st quarter worth approximately $44,000. SG Americas Securities LLC purchased a new stake in LENZ Therapeutics during the third quarter worth $107,000. Marquette Asset Management LLC acquired a new stake in LENZ Therapeutics during the first quarter valued at $131,000. Squarepoint Ops LLC purchased a new position in LENZ Therapeutics in the second quarter valued at $181,000. Finally, Rhumbline Advisers raised its position in shares of LENZ Therapeutics by 265.6% in the second quarter. Rhumbline Advisers now owns 16,812 shares of the company’s stock worth $291,000 after acquiring an additional 12,214 shares during the period. 54.32% of the stock is currently owned by hedge funds and other institutional investors.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.